酒精性肝病相关肝细胞癌与其他病因所致肝细胞癌的差异

摘要/Abstract

摘要： 酒精性肝病相关肝细胞癌(ALD-HCC)作为肝细胞癌(HCC)的第三大病因,在流行病学特征、临床表型、发病机制、诊断与治疗响应等方面,与病毒性肝炎(HBV/HCV)相关HCC及代谢功能障碍相关脂肪性肝病(MASLD)相关HCC存在显著差异。本文系统梳理ALD-HCC与其他病因HCC的核心差异,为临床精准诊疗及预防策略提供参考。

关键词: 酒精性肝病, 肝细胞癌, 代谢功能障碍酒精性肝病, 代谢功能障碍相关脂肪性肝病

周靖媛, 周嘉, 柳涛, 高沿航. 酒精性肝病相关肝细胞癌与其他病因所致肝细胞癌的差异[J]. 肝脏, 2025, 30(8): 1028-1032.

/ 推荐

[1] Huang D Q, Singal A G, Kono Y, et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer [J]. Cell Metabolism, 2022, 34(7): 969-977.e2.
[2] Devarbhavi H, Asrani S K, Arab J P, et al. Global burden of liver disease: 2023 update [J]. Journal of Hepatology, 2023, 79(2): 516-537.
[3] Mcglynn K A, Petrick J L, El-Serag H B, et al. Epidemiology of hepatocellular carcinoma [J]. Hepatology, 2020, 73(S1): 4-13.
[4] Zhang C H, Cheng Y, Zhang S, et al. Changing epidemiology of hepatocellular carcinoma in Asia [J]. Liver International, 2022, 42(9): 2029-2041.
[5] Bucci L, Garuti F, Camelli V, et al. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome [J]. Aliment Pharmacol Ther, 2016, 43(3): 385-399.
[6] Huang D Q, Mathurin P, Cortez-pinto H, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors [J]. Nat Rev Gastroenterol Hepatol, 2023, 20(1): 37-49.
[7] Batt N M, Rodrigues B, Bloom S, et al. Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy [J]. J Gastroenterol Hepatol, 2024, 39(6): 1048-1056.
[8] Yue T, Xu M, Cai T, et al. Gender disparity and temporal trend of liver cancer in China from 1990 to 2019 and predictions in a 25-year period [J]. Front Public Health, 2022, 10: 956712.
[9] Costentin C E, Sogni P, Falissard B, et al. Geographical disparities of outcomes of hepatocellular carcinoma in France: the heavier burden of alcohol compared to hepatitis C [J]. Dig Dis Sci, 2020, 65(1): 301-311.
[10] Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease [J]. J Hepatol, 2019, 70(2): 284-293.
[11] Gratacós-ginès J, Ariño S, Sancho-bru P, et al. MetALD: clinical aspects, pathophysiology and treatment [J]. JHEP Rep, 2025, 7(2): 101250.
[12] Yun B, Park H, Ahn S H, et al. Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: a nationwide study [J]. Am J Gastroenterol, 2025, 120(2): 410-419.
[13] Zeng R W, Ong C E Y, Ong E Y H, et al. Global prevalence, clinical characteristics, surveillance, treatment allocation, and outcomes of alcohol-associated hepatocellular carcinoma [J]. Clin Gastroenterol Hepatol, 2024, 22(12): 2394-2402.e15.
[14] Jacob R, Prince D S, Kench C, et al. Alcohol and its associated liver carcinogenesis [J]. J Gastroenterol Hepatol, 2023, 38(8): 1211-1217.
[15] Seo W, Gao Y, He Y, et al. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles [J]. J Hepatol, 2019, 71(5): 1000-1011.
[16] Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis [J]. Nat Genet, 2015, 47(12): 1443-1448.
[17] Jiang Y, Han Q, Zhao H, et al. The mechanisms of HBV-induced hepatocellular carcinoma [J]. J Hepatocell Carcinoma, 2021, 8: 435-450.
[18] Vescovo T, Refolo G, Vitagliano G, et al. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma [J]. Clin Microbiol Infect, 2016, 22(10): 853-861.
[19] Singal A G, Yopp A C, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process [J]. Cancer Prev Res (Phila), 2012, 5(9): 1124-1130.
[20] Beale G, Chattopadhyay D, Gray J, et al. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease [J]. BMC Cancer, 2008, 8: 200.
[21] Saito M, Yano Y, Hirano H, et al. The serum level of NX-DCP-R, but not DCP, is not increased in alcoholic liver disease without hepatocellular carcinoma [J]. Cancer Biomark, 2016, 16(1): 171-180.
[22] Lehrich B M, Zhang J, Monga S P, et al. Battle of the biopsies: role of tissue and liquid biopsy in hepatocellular carcinoma [J]. J Hepatol, 2024, 80(3): 515-530.
[23] Simmons O, Fetzer D T, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis [J]. Aliment Pharmacol Ther, 2017, 45(1): 169-177.
[24] Mokrane F Z, Lu L, Vavasseur A, et al. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules [J]. Eur Radiol, 2020, 30(1): 558-570.
[25] Yang X, Yang C, Zhang S, et al. Precision treatment in advanced hepatocellular carcinoma [J]. Cancer Cell, 2024, 42(2): 180-197.
[26] Pfister D, Núñez N G, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC [J]. Nature, 2021, 592(7854): 450-456.
[27] Bruix J, Raoul J L, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial [J]. J Hepatol, 2012, 57(4): 821-829.
[28] Lo C M, Ngan H, Tso W K, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma [J]. Hepatology, 2002, 35(5): 1164-1171.
[29] Ganne-Carrié N, Nahon P, Chaffaut C, et al. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance [J]. JHEP Rep, 2021, 3(3): 100285.
[30] Costentin C E, Mourad A, Lahmek P, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective, nationwide study [J]. Cancer, 2018, 124(9): 1964-1972.

酒精性肝病相关肝细胞癌与其他病因所致肝细胞癌的差异

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨啸天, 张颖, 郑昕. 乙型肝炎病毒相关肝细胞癌复发的空间——免疫研究进展[J]. 肝脏, 2025, 30(8): 1023-1025.
[2]	庄启程, 杨长青. 拉尼兰诺治疗代谢功能障碍相关脂肪性肝炎的机制与临床研究进展[J]. 肝脏, 2025, 30(8): 1036-1038.
[3]	朱冉, 陈淑娆, 邹梦琦, 杨宇峰. 早发性肝细胞癌与非早发性肝细胞癌的临床病理特征比较[J]. 肝脏, 2025, 30(8): 1093-1096.
[4]	刘丁境, 牛日雨, 尹伟, 李成忠. 血小板相关参数评估乙型肝炎病毒相关肝细胞癌发生风险和预后的研究进展[J]. 肝脏, 2025, 30(8): 1165-1168.
[5]	李卉, 周义文, 王务军, 陈江波. 微波消融联合信迪利单抗对中晚期肝细胞癌患者疾病控制效果、免疫功能及预后的影响[J]. 肝脏, 2025, 30(7): 934-937.
[6]	李晓艳, 张景芳, 王春萍, 周平安. 超声造影联合CT定量参数鉴别诊断肝脏局灶性结节增生与肝细胞癌的价值研究[J]. 肝脏, 2025, 30(7): 938-942.
[7]	杨斌, 王勇刚, 曹洪刚, 高建勇. HBV相关肝细胞癌患者血清UCA1、WRAP53表达水平及其临床意义[J]. 肝脏, 2025, 30(7): 943-947.
[8]	李龙, 郑振东, 杜成, 刘渤娜. HCC患者接受营养干预后BMI、PNI、NPAR水平变化及其对生存质量的影响[J]. 肝脏, 2025, 30(7): 948-952.
[9]	芮龙, 周绵, 董艳丽, 孙颖. 晚期肝细胞癌系统治疗的进展与优化策略[J]. 肝脏, 2025, 30(6): 759-763.
[10]	葛具燕, 徐秀娟. 肝细胞癌及其双表型肝脏影像学及临床病理特征分析[J]. 肝脏, 2025, 30(6): 777-780.
[11]	路子瑶, 杨松. 酒精性肝病命名的中西方差异[J]. 肝脏, 2025, 30(5): 584-587.
[12]	周嘉, 周靖媛, 柳涛, 高沿航. 巨噬细胞在酒精性肝病中作用机制研究进展[J]. 肝脏, 2025, 30(5): 588-591.
[13]	王辉, 边娜娜, 冯巩, 张粉娜, 孙荣荣, 张心怡, 王梓依, 贺娜. EGF rs4444903基因多态性与HCV感染相关肝细胞癌风险相关:一项Meta分析[J]. 肝脏, 2025, 30(5): 624-629.
[14]	谭舒丹, 王统华, 程吉云, 郭瑜修, 蓝常明, 余贤恩. 系统免疫炎症指数在肝细胞癌TACE术后的临床意义[J]. 肝脏, 2025, 30(5): 633-637.
[15]	陈慧洁, 彭舟, 张琴. 祛脂方调控ITGB6/IL23A/STAT3信号通路改善MASH相关肝纤维化[J]. 肝脏, 2025, 30(5): 675-682.